Avoro Capital Advisors’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-1,885,000
Closed -$257M 51
2020
Q3
$257M Buy
1,885,000
+5,000
+0.3% +$532K 3.65% 6
2020
Q2
$182M Buy
1,880,000
+445,000
+31% +$37.1M 3.59% 9
2020
Q1
$67.3M Sell
1,435,000
-105,000
-7% -$6.73M 2.27% 17
2019
Q4
$112M Sell
1,540,000
-12,700
-0.8% -$770K 3.3% 12
2019
Q3
$81M Buy
1,552,700
+177,700
+13% +$9.45M 3.38% 11
2019
Q2
$68.9M Buy
1,375,000
+375,000
+38% +$18.3M 2.38% 15
2019
Q1
$52M Buy
+1,000,000
New +$46.1M 2.25% 13
2018
Q1
Sell
-398,207
Closed -$16.8M 63
2017
Q4
$16.8M Hold
398,207
1.09% 23
2017
Q3
$17.1M Buy
+398,207
New +$12.7M 1.32% 23

Avoro Capital Advisors's MYOK Position: Q4 2020 in Review

Avoro Capital Advisors sold out of MyoKardia, Inc. Common Stock (MYOK) in Q4 2020, closing a stake of 1,885,000 shares — an estimated $257M sold.

Avoro Capital Advisors first reported a position in MYOK in Q3 2017 and held it in 9 quarters. The position peaked at $257M in Q3 2020. 0 funds tracked by Wall St. Rank hold MYOK as of Q4 2020.

  • Avoro Capital Advisors reported no remaining MyoKardia, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Avoro Capital Advisors sold 1,885,000 MyoKardia, Inc. Common Stock shares in Q4 2020, an estimated $257M.
  • Avoro Capital Advisors first reported a position in MyoKardia, Inc. Common Stock in Q3 2017 and held it in 9 quarters.
  • Avoro Capital Advisors's MyoKardia, Inc. Common Stock position peaked at $257M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q4 2020.

Based on Avoro Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.